The Institute for Clinical and Economic Review claims that the first disease-modifying treatment for Alzheimer’s disease isn’t worth its cost. But the economists omit several key considerations about the devastating neurodegenerative disease.
ICER’s Evaluation of Alzheimer’s Treatment Undervalues Key Groups
